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Abstract:  
Stanford Medicine is building a new data platform for our academic research community 
to do better clinical data science. Hospitals have a large amount of patient data and 
researchers have demonstrated the ability to reuse that data and AI approaches to 
derive novel insights, support patient care, and improve care quality.  However, the 
traditional data warehouse and Honest Broker approaches that are in current use, are 
not scalable. We are establishing a new secure Big Data platform that aims to reduce 
time to access and analyze data. In this platform, data is anonymized to preserve 
patient data privacy and made available preparatory to Institutional Review Board (IRB) 
submission. Furthermore, the data is standardized such that analysis done at Stanford 
can be replicated elsewhere using the same analytical code and clinical concepts. 
Finally, the analytics data warehouse integrates with a secure data science 
computational facility to support large scale data analytics. The ecosystem is designed 
to bring the modern data science community to highly sensitive clinical data in a secure 
and collaborative big data analytics environment with a goal to enable bigger, better and 
faster science. 
Background: 
Healthcare is at a nexus where the data generated during the course of clinical care or 
research can be used to advance both the science and practice of medicine. With the 
widespread adoption of electronic health records (EHR), driven by the Health 
Information Technology for Economic and Clinical Health (HITECH) Act  of 2009 
[Gold2016], most academic centers now have more than ten years of EHR data 
available for reuse. [Lowe2009, Evans2012, Danciu2014, Kunjan2015, Turley2016, 
Foran2017]. In addition, hospitals have a fast growing amount of data from sources 
such as radiology, pathology, and bedside monitoring that are ripe for reuse to improve 
patient care and to advance scientific discovery [Shah2019, Rajkomar2019]. A sampling 
of research in recent years at Stanford [Banda2019, Banerjee2019, Dunnmon2019, 
Gombar2019, Hernandez-Boussard2016, Hernandez-Boussard2019, Jung2019, 
Parthipan2019, Rajpurkar2018, Ross2019, Tamang2015, Tamang2017a, 
Tamang2017b, Wang2018]  suggests that researchers are able to reuse the collected 
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data to derive novel insights, support patient care, and improve care quality using 
Artificial Intelligence (AI) approaches. Such efforts can improve the standard of care 
today [Gombar2019, Jung2019] and also hold the promise to improve health outcomes 
and reduce cost of care in the coming years [Tamang2017b].  
Stanford’s efforts to explore the use of AI in Medicine (AIM) started in the 1970s with the 
Stanford University Medical EXperimental computer for Artificial Intelligence in Medicine 
(SUMEX-AIM) project [Kulikowski2019], a national computer resource (1973-1992) 
funded by NIH to promote applications of AI to biological and medical problems.  Over 
the past decade, Stanford School of Medicine Dean’s Office has made significant 
investment in support of a clinical data ecosystem for use for research. Stanford’s first 
generation Clinical Data Warehouse (CDW), STRIDE - Stanford Translational Research 
Integrated Database Environment [Lowe2009], has been serving Stanford research 
community since 2008.  
STRIDE has an associated cohort building tool, Anonymous Patient Cohort Discovery 
Tool [Lowe2009], that returns patient counts matching a given query and is used to 
design studies prior to Institutional Review Board (IRB) submission. The tool is 
designed to answer the question “How many patients in the CDW contain these 
attributes?” No individual patient data is exposed during cohort search. A chart review 
tool, accessible after IRB approval [Grady2015],  allows rapid view of the retrieved 
patient cohort. In addition, there is a real time Complex Event Processing (CEP) engine 
[Weber2010], that uses HL7 feeds to identify potential research participants. 
Stanford’s Honest Broker [Choi2015], in part funded by Dean’s Office and in part funded 
by the National Center for Advancing Translational Sciences (NCATS) Clinical and 
Translational Science Awards (CTSA), is composed of two teams. The Research IT 
team (RIT) at Technology & Digital Solutions has performed the role of data stewards 
since the release of STRIDE in 2008. RIT transfers data from our hospitals, normalizes 
the data for research use, develops Cohort and Chart review tools, develops 
de-identification pipelines and supports end users. The Research Informatics Center 
(RIC) in the Dean’s Office represents the analytics team and was split up from RIT in 
2017 and supports custom query development and extraction. The Honest Broker 
teams have provided over 5000 clinical data consults since 2008 resulting in hundreds 
of publications, including many that employ machine learning and other forms of AI 
techniques. The numbers have increased year over year. In 2019, approximately 650 
studies involving 530 PIs and 1500 researchers were approved by IRB. Approximately 
58% of the approved IRBs could use the existing STRIDE cohort and chart review tools 
in a self-service manner. The Honest Broker teams served over 800 consultations 
including both pre and post-IRB support.  
Vision: 
There is an appetite for diverse data types at Stanford as illustrated by a sampling of 
publications, ​e.g.​, radiology [Dunnmon2019, Patel2020], echocardiography 
[Dykes2019], and bedside monitoring [Miller2018]. Our Hospitals are currently accruing 
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research usable data at a petabyte scale. For example, the current rate of growth for 
radiology and echo data is estimated at 450 TB/yr, bedside monitoring is estimated at 
100 TB/yr, digital pathology at 1000 terabytes/yr. Research IT is starting to bring these 
datasets in a new STAnford medicine Research data Repository (STARR, 
http://starr.stanford.edu​) with the intent of a) making these rich but often proprietary 
sources of data “analysis-ready”, b) linking the data to Clarity for “completeness”, and c) 
bringing in ancillary data sources (e.g. PowerPath for digital pathology) to make the 
data metadata “rich”. Our intent is to support the necessary data warehouses, data 
models, identified or anonymized non-human subject data, and analytical tools based 
on the data in STARR. 
We also envision a world where we can bring more scientists to data, do better team 
science while preserving patient privacy, fail fast and innovate faster, and bring 
innovations to patients in a timely fashion. 
Motivation: 
Our existing ecosystem of STRIDE CDW, Cohort and Chart review tools, and our 
Honest Broker services are unable to keep up with growing demand for greater volume 
and complexity of data. Researchers are waiting longer for IRB approval, privacy, and 
security reviews, and Honest Broker services.  In this section, we motivate our new 
clinical data science platform by discussing the gap between our current capabilities 
and our vision.  
 
Firstly, the current system does not allow researchers to do self-service exploratory data 
analysis. Researchers get access to patient data either by filing an IRB request for 
identified patient data (not exploratory) or via an Honest Broker consultation for 
anonymized data (not self service). With the growing demand for data, the demand for 
IRB and Honest Broker services are rising. Growing number of researchers are 
frustrated with delays in starting their projects due to the arduous IRB process 
[Silberman2011].  The current system is not designed to support the growing 
enthusiasm for AI driven research.  
 
We can reduce researcher reliance on Honest Broker services by enabling self-service 
pre-IRB access to anonymized EHR data. The idea of using anonymized CDW for 
pre-IRB studies is not new [Liu2009] and exists at other academic centers like UCSF 
(​https://informationcommons.ucsf.edu/​). We expect that pre-IRB access to anonymized 
data will enable research teams to start their studies earlier and publish sooner. For 
example, with anonymized data a team may realize the need for advanced statistics 
skillset to account for the inherent biases in EHR data [Verheji2018] much before their 
IRB request is approved. In some cases, researchers will realize that the underlying 
data doesn’t serve the original study requirements and consequently, they will avoid the 
arduous IRB process and reduce their cost. Finally, many researchers will be able to 
complete their research studies with anonymized data and will reduce the number who 
eventually need access to identified data thus reducing the likelihood of privacy 
breaches. In summary, enabling pre-IRB access to anonymized EHR data in a 
  
4 of 18 
self-service fashion will reduce several of our current research bottlenecks and result in 
faster and better research outcomes. 
Secondly, researchers find it difficult to extend their studies on Stanford datasets to 
non-Stanford data sources. The difficulty arises because we use a data model, STRIDE, 
that is idiosyncratic and non-standard. To extend the studies to alternate data sources, 
researchers engage in the complex legal process of data sharing agreements and then 
spend enormous resources transforming the data from one format to another. We 
propose to standardize on Observational Health Data Sciences and Informatics 
(OHDSI) Observational Medical Outcomes Partnership (OMOP) Common Data Model 
(CDM) [Hripcsak2015], a data model that is widely used by other universities and 
institutions. The utility of standardization is interoperability [Wilkinson2016] and is 
demonstrated across hundreds of studies in the clinical data research networks 
[McCarty2011, Visweswaran2018, Platt2018]. This standardization will mean that 
Stanford researchers will be able to extend their studies to non-Stanford datasets faster 
and with ease, while also benefiting from and contributing to the large community of 
researchers contributing to analytical method development [Vashisht2018, Wang2020].  
Our choice of OMOP CDM is motivated by multiple factors. There are a number of 
popular CDMs to choose from including i2b2 [Murphy2006, Weber2009], Pediatric 
Learning Healthcare System PEDSNet [Forrest2014], Patient-Centered Clinical 
Research Network PCORNet  [Fleurence2014], Health Care Systems Research 
Network [Ross2014], and the US Food and Drug Administration Sentinel [Curtis2012]. 
Choosing a particular CDM over another is a matter of meeting specific research 
objectives [Kahn2012, Ogunyemi2013, Huser2013, Xu2015].  We choose OHDSI 
OMOP CDM for its demonstrated applicability for many different use cases including a) 
claims and EHR [Overhage2012], b) EHR based longitudinal registries [Garza2016] 
and, c) Hospital transactional database [Makadia2014]. Stanford data in OMOP CDM 
pilot phase has resulted in several successful studies [Agarwal2016, Banda2016, 
Hripcsak2016, Duke2017, Vashisht2018]. The OMOP CDM demonstrates strong results 
in comparative effectiveness research [Ogunyemi2013] with minimal information loss 
during data transformation [Voss2015], speeds up implementation of clinical 
phenotypes across networks [Hrispack2019], and promotes research reproducibility 
[Zhao2018]. There is demonstrated interoperability between different CDMs 
[Klann2018] so choosing OMOP does not exclude support for other CDMs in future. 
Furthermore, there is a strong focus in OHDSI community on data quality and broad 
support for the analytical toolkits (aka methods library) that together strive to deliver 
consistency in cohort definition, analysis design, and reporting of results. Perhaps the 
most appealing aspect is that OHDSI is an open source public-private partnership and 
welcomes community participation. There is a robust community of end users, 
developers and thought leaders who are actively engaged in various shared 
repositories, discussion forums, training and workshops. The collection of learning 
resources are vast (​https://github.com/OHDSI/​) and includes FAQs, code snippets and 
video lectures. Finally, OMOP is adopted at other CTSA sites ​e.g.​, Albert Einstein 
College of Medicine – Montefiore Health, Columbia University, Icahn School of Medicine 
at Mt. Sinai. 
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Thirdly, current research computing infrastructure is not suited to modern clinical data 
science. Security issues are significant when handling patient data. It has been shown 
that even anonymized patient data can be combined with other publicly available data to 
re-identify patients [Emam2011]. In the hands of a malicious attacker, re-identification 
can lead to potential harm for vulnerable groups. Clinical notes, even when 
anonymized, may contain incidental PHI. Researcher laptops, which are secured by 
Stanford IT, have insufficient storage and compute to support complex analyses on 
these datasets. Large scale shared computing environments at Stanford, such as 
Sherlock (​https://www.sherlock.stanford.edu/​), have the required storage and compute, 
but are not designed for sensitive patient data. Further, requiring individual labs or 
researchers to set up servers and manage constantly evolving security issues is 
infeasible, there are a number of well-publicized significant OS and/or architectural 
vulnerabilities (​https://nvd.nist.gov/​) in any year that require sophisticated IT expertise. 
We built a shared data science platform that is both secure and can provide the 
necessary computational power where researchers can run common data science 
workflows (e.g. TensorFlow using GPGPUs). We believe that such a platform will speed 
up novel computationally intensive healthcare research such as advanced phenotyping 
[Deisseroth2018], radiology [Dunnmon2019, Patel2020], echocardiography 
[Dykes2019], and bedside monitoring [Miller2018]. It will also improve patient data 
security, and reduce institutional risks. 
Methods: 
In this section, we outline the methods used in meeting the three objectives, a) enabling 
self-service pre-IRB access to anonymized EHR data, b) standardizing the data, and c) 
supporting researchers on a secure data science platform. Details of these methods are 
available in the Supplementary section. 
Stanford EHR has over a hundred million clinical notes and our goal is to support 
monthly data refresh. We therefore need a secure infrastructure to support scalable 
storage and data processing. We expand our HIPAA compliant data center that hosts 
STRIDE to incorporate a public cloud, Google Cloud Platform (GCP), and use a mix of 
on-premise private cloud and public cloud capabilities. The hybrid infrastructure meets 
Stanford’s data governance requirements (Supplementary material, Section 1) and 
minimum security requirements (Supplementary material, Section 2). To support the 
growing number of researchers using the EHR data, we use cloud native high 
performance analytical data warehouse Google BigQuery platform (Supplemental 
material, Section 3) to host and query the data. We adopt open source cloud agnostic 
workflow runner (Supplementary Material Section 4) for processing data. We anonymize 
all data including clinical text using best-in-class de-identification methods 
(Supplementary material, Section 6).  
We normalize the EHR data to OMOP CDM v 5.3.1 (Supplementary Material Section 5) 
in a new analytical warehouse, STARR-OMOP.  The NOTE table in OMOP is used to 
store the anonymized clinical text. Additionally, we populate the NOTE_NLP table to 
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improve cohort design [Edinger2017]. We use a method that has incorporated both 
negation detection and history detection to convert clinical terms to known medical 
concepts (Supplementary material, Section 7).  
For a secure data science facility, we collaborate with Stanford’s Research Computing 
(SRC) team, to build a STARR integrated secure data science platform, Nero 
(Supplementary material, Section 8). Nero is HIPAA compliant and supports Big Data 
analytics. Armed with modern containerization and container orchestration technologies, 
the SRC team provides a range of services including hardware procurement and 
maintenance, OS upgrades, cloud integration, security requirements to meet HIPAA 
compliance, tool integration and research computing support. Researchers simply need 
to request access to the secure platform, but otherwise, need not worry about hardware 
procurement, and system security. In addition to data science tools such as Jupyter 
notebook, Python, anaconda, TensorFlow, RStudio, SAS etc., the data science platform 
supports OHDSI analytical tools. 
Researchers directly access the anonymized non-human-subject dataset, 
STARR-OMOP-deid,  in the secure Nero platform (Supplementary material, Section 9). 
The identified STARR-OMOP is available to the Honest Broker team on Nero and the 
researcher can seek post-IRB OMOP data after IRB approval via the Honest Broker 
team. Finally, data science training [Dolezel2019] is an important aspect of making the 
data self service. As a result, with support from Stanford CTSA award, RIT has 
launched training (Supplementary material, Section 10) on the use of the new 
anonymized data warehouse. 
Analytics: 
In this section, we outline the analytics derived from our new OMOP database and 
usage for our new data science platform.  
 
We present analytics from our OMOP conversion using NCATS  CTSA Common 
Metrics ((​https://ncats.nih.gov/ctsa/projects/common-metrics​)) in Table S5 
(Supplementary material, Section 5). We show that OMOP database has ~2.7 million 
patients, over 60% of the patients have a diagnosis (ICD 9/10), over 40% have 
medication information (RxNorm), ~75% have lab information (LOINC), and over 90% of 
patients have clinical notes. In figure S5.1 and table S5.2 we show the enhancement in 
standardized concepts over raw Clarity data. 
 
We present analysis of PHI rate observed in our clinical text processing. Approximately, 
100 million clinical notes are processed. These contain 33 billion words, the median 
number of words per clinical note is ~100 (Figure S5, Supplementary material, Section 
5). There are ~22 million notes with no PHI findings, and ~1.3M notes with more than 
100 PHI findings. Of the ~33 billion words, 1.4 billion are determined as PHI findings 
i.e.​, approximately 4% of the words are found to be PHI (Figure S6.4, Supplementary 
material, Section 6). We also present the distribution of different PHI types (e.g. name, 
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MRN, date) found in the notes and success rate of methods in finding these PHI e.g., 
NLP vs patient look up (Figure S6.5, Supplementary material, Section 6). 
 
We present the number and percent of medical concepts found via text processing in 
Table S7 (Supplementary material, Section 7). Nearly 2 billion concepts (122K unique 
concepts) are found in 33 billion words representing 14 different vocabularies. 
 
Finally, we present the performance of Google BigQuery. In Table S3 (Supplementary 
material, Section 6), we compare Oracle vs BigQuery and show that BigQuery is 
10-100x faster. In Table S9.1, we present the aggregate statistical performance of 
running Achilles Heel, data characterization queries, on STARR-OMOP dataset. Out of 
a total of 725 queries available in Achilles, an impressive 660 queries took less than 17 
seconds, and median execution time was 3 sec. The longest query took 20 min and 
processed 13 GB of data. We expect that the research community will similarly 
experience ultra fast performance when using the STARR-OMOP-deid for analysis.  
 
In table S9.3, we present performance of ATLAS running on Google Cloud using 
Google BigQuery against postgreSQL using  the commonly available ​Medicare Claims 
Synthetic Public Use datafiles (DE-SynPUF, 
https://www.cms.gov/Research-Statistics-Data-and-Systems/Downloadable-Public-Use-
Files/SynPUFs/DE_Syn_PUF​). ​The OHDSI SqlRender package 
(​https://github.com/OHDSI/SqlRender​) and JDBC drivers require performance tuning to 
support a new database type, in this case, BigQuery. ​In nearly all cases, the 
performance of ATLAS is comparable or faster when using BigQuery.  
 
The Nero platform was launched in the summer of 2018.  Nero has on-boarded 400 
researchers representing 60 Stanford Principal Investigators. These researchers are 
working on High Risk data of various types, ​i.e.​, not limited to biomedical data.  Over 
200 TB of storage has already been provisioned and we see a strong growth in use of 
GPGPUs on-premise. The STARR-OMOP-deid dataset was launched in the fall of 
2019. A small subset of our Nero research community, ~30, have completed the user 
training at the time of writing. The ATLAS (​https://ohdsi-atlas.stanford.edu/​) was 
launched in early 2020. 
 
We propose to present the research impact of the new solutions in a subsequent 
manuscript. We are also in the process of running network studies using the OMOP 
database and case studies demonstrating the clinical text processing and will present 
the results in subsequent manuscripts. 
Future work: 
We are bringing in other data types in STARR such as radiology, bedside monitoring 
and pathology.  We propose to extend the methods proposed in meeting the three 
objectives, a) enabling self-service pre-IRB access to anonymized EHR data, b) 
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standardizing the data, and c) supporting researchers on a secure data science 
platform, to these other data types.  
For example, we can link the datasets first, and then de-identify using the same protocol 
such that the HIPAA identifiers are deterministic anonymized across all datasets to 
preserve the linking.  
For standardization of other data types, OMOP CDM does not offer a complete solution 
yet. However, such data can be captured using other well defined standards. For 
example, radiology Picture Archiving and Communication System (PACS) data is 
currently in pilot in OMOP CDM (​https://github.com/OHDSI/Radiology-CDM​), but the 
underlying DICOM (Digital Imaging and Communications in Medicine, 
https://www.dicomstandard.org/​) data type is a well defined standard for radiology. RIT 
is building a metadata dataset that contains all metadata from images in the PACS 
Vendor Neutral Archive. This dataset can be linked to the OMOP dataset via image 
accession IDs and allow researchers a) unprecedented search capability and, b) run AI 
models taking the confounding factors such as device models [Badgeley2019] into 
account. For example, researcher can query the number of studies where patients have 
neurodegeneration and the image has annotations stored in Grayscale Softcopy 
Presentation State Storage (GSPS) Service-Object Pair (SOP) class, to estimate the 
effort in building test sets for their AI model. We have an image de-identification pipeline 
that is built for petascale data processing and can support both metadata and pixel 
scrubbing. We propose to present the pipeline in a subsequent manuscript.  
Research IT’s data center that hosts STARR and related portfolio of data warehouses 
and tools and data science platform, Nero, are designed for petascale data processing 
and team science respectively. We expect to integrate with other cloud platforms like 
AWS and Azure in time. 
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Supplementary Material 
In the supplementary material, we present details of data governance, data security 
implementation, technological and scientific methodologies used to generate the 
anonymized and standardized database, the secure data science environment and user 
support. 
Section 1: Data governance policies 
In this section, we present the data governance requirements for access to patient data, 
both anonymized and identified, and our workflow to meet the requirements.  
The raw data in STARR data lake is Protected Health Information and is governed by 
the standards for privacy of individually identifiable health information by U.S. 
Department of Health and Human Services [HHS2002]. Research access to identified 
data (e.g., the identified STARR-OMOP) requires the researcher to get IRB approval 
specific to their study.  
The requirements for the security and privacy of health information established by the 
Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule and HITECH 
Act explicitly do not apply to the protected health information (PHI) that has been 
de-identified, provided that there is “no reasonable basis to believe that the information 
can be used to identify an individual”. Such de-identified or limited data sets do not 
require IRB approval, only Privacy Board Review and an appropriate Data Use 
Agreement. 
 
Figure S1: Data governance for the STARR-OMOP dataset 
This document is supplemental to the main manuscript, “A new paradigm for accelerating clinical data science at Stanford Medicine” 
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The workflow is illustrated in Figure S1. Research IT de-identifies the patient data 
(Section 6), in STARR-OMOP, into an anonymized dataset STARR-OMOP-deid and 
undertakes the Privacy Board Review. For the STARR-OMOP-deid dataset to be 
classified as non human subject research, Research IT does not allow subsequent 
linking the de-identified person IDs in the anonymized dataset to patient MRNs.  
Researchers as part of STARR-OMOP-deid data access, sign a DUA referred to as a 
Data Privacy Attestation that prohibits recipients of anonymized data from attempting to 
re-identify the data subjects, or from resharing the data without permission.  
Patient data anonymization is required but is not sufficient to maintain privacy. It has 
been shown that de-identified data can be combined with other publicly available data to 
re-identify patients [Emam2011]. If the de-identified data is put on servers that are 
subsequently compromised, the data can make its way to a malicious privacy hacker 
and re-identification can lead to potential harm for vulnerable groups such as patients 
who may face social repercussions due to their LGBQ status, substance abuse, 
sexually transmitted diseases, suicidal ideations, or mental health issues. Therefore, for 
data security, STARR-OMOP-deid data is only available in a highly secure computing 
and storage environment, Nero (Section 8). 
Section 2: Security management 
In this section, we present the data security requirements and our security methods. 
Stanford University Information Security Office (ISO) provides risk classification for 
various data types (​https://uit.stanford.edu/guide/riskclassifications​). The anonymized 
STARR-OMOP-deid is classified as High Risk data, we believe that loss of 
confidentiality, integrity, or availability of such data could have a significant adverse 
impact on our mission, reputation and safety. The technical reason for the High Risk 
classification is the potential of incidental PHI in the de-identified clinical text. However, 
as mentioned previously,  de-identified clinical data carries re-identification risk 
[Emam2011], and safeguarding this data to strictest standards minimizes such 
re-identification risks. Stanford ISO also provides minimum security guidelines 
(​https://uit.stanford.edu/guide/securitystandards​) for different data risk classifications. 
RIT’s infrastructure is required to meet the minimum security guidelines for HIPAA and 
High Risk data.  
The minimum security standards for High Risk data lead to complex set of IT 
requirements for servers and laptops that access such data.  For example, endpoints 
such as laptops used by researchers to view data, need to be encrypted, backed up, 
inventoried, malware protected and patched regularly. Stanford laptops are configured 
and managed to meet these requirements and prior to CDW data access, user is 
required to complete an “AM I Encrypted (aka amie)” attestation that is monitored by 
Stanford School of Medicine. Servers additionally require firewall protection, intrusion 
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detection, centralized logging among other requirements. All systems are required to 
support two-factor authentication and Research IT additionally supports Stanford’s two 
factor authentication. All systems with High Risk data are required to support audit 
capabilities.  
For scalability, we expanded our on-premise data center to cloud. Google Cloud 
Platform (GCP) is our first cloud based data center. Under Stanford’s business 
arrangements, while GCP hosts Stanford data, Google does not have access to 
Stanford data. Infrastructure-as-a-Service (IaaS) and Software-as-a-Service (SaaS) 
providers such as GCP are required to be covered under a Business Associate 
Agreement (BAA) if the data resides on provider platforms. However, a BAA is a 
necessary but not sufficient condition for data security. Cloud services such as GCP or 
Amazon Web Services (AWS) used by RIT need to be secured by RIT to meet ISO 
security guidelines for minimum security including guidelines for ephemeral services, 
containerized solutions, credential and key management. We only use cloud services 
that are covered under Stanford BAA. For example, for Google Cloud Platform, we use 
the HIPAA compliant services covered under Stanford-Google BAA 
(​https://cloud.google.com/security/compliance/hipaa-compliance/​). Our approach to 
securing a Cloud IaaS provider is further described in a prior manuscript [Datta2016]. 
Both the STARR and Nero data science platform use containers heavily. Containers 
allow a developer to package up an application with all of the parts it needs, such as 
libraries and other dependencies, and ship it all out as one package. This ability not only 
streamlines software deployment and security management [NISTSP800-190], it 
improves user experience and results in a reproducible analytics environment.  We use 
both Docker (​https://www.docker.com/why-docker​) and Singularity 
(​https://sylabs.io/singularity/​). Docker is used  for Cloud and on-premise infrastructure 
management. Singularity is a secure container technology that is particularly well suited 
for researcher (non system admin role) use in HPC environments. Stanford has been 
one of the early adopters of Singularity for HPC clusters [Kurtzer2017] and as a result, 
the Stanford Research Computing Center (SRCC) team has tremendous experience 
supporting our scientific research community using containerized application bundles.  
While minimum security requirements may be clear, their implementation is often 
complex. For the on-premise servers, OS vulnerability management is a constant effort. 
Cloud providers take on the burden of maintaining secure OS images. On cloud, the 
complexity often comes from our lack of control over cloud products. For example, cloud 
providers may introduce features that unwittingly encourage users to export or use data 
in a non-approved or non-compliant manner. We may not be able to disable those 
features in a meaningful manner, and attempting to train users not to use those features 
may be ineffective. Furthermore, the default permission models do not distinguish very 
effectively between project resource visibility (configuration, metadata, resources, 
billing, etc.) and High Risk data visibility. It is often hard and complicated to provide 
effective separation of duties. Finally, the Cloud services are evolving over time, and the 
various products are not necessarily compatible with each other at a given point in time. 
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For example, Healthcare APIs and Cloud SQL import/export don't work with VPC 
Service Controls at the time of writing. 
Both STARR and Nero go through Stanford Data Risk Assessment (DRA) process 
(​https://uit.stanford.edu/security/dra​) overseen by ISO and UPO. The DRA process is 
required at Stanford for new High Risk infrastructure or significant changes to existing 
infrastructure. These platforms also go through external penetration testing from time to 
time and ISO is part of the team that selects the pentest service provider, reviews the 
testing protocol and the final report. Prior to the launch of ATLAS Cohort tool 
(​https://ohdsi-atlas.stanford.edu/​), we completed an external penetration testing and 
addressed the vulnerabilities in collaboration with ATLAS development team.  
Section 3: Database technologies 
In this section, we describe various database technologies used in our warehouses and 
provide justification for selection. 
Our workflows move data from on-premise relational databases (e.g. Microsoft MSSQL) 
to cloud native distributed databases (e.g. Google Cloud BigQuery) via Apache Avro 
(​https://avro.apache.org/​) format. Avro provides interoperability for databases at rest. 
Avro is an open, compact binary data serialization format for data intensive application 
with wide vendor support. Avro files are self-describing (they include the schema) and 
are the preferred file storage format for many popular Big Data systems such as Apache 
Hadoop (​https://hadoop.apache.org/​), Google BigQuery, and Amazon Redshift 
(​https://aws.amazon.com/redshift/​). Avro has support for a variety of programming 
languages such as Java, Scala, C, C++ and Python [Maeda2012]. Avro uses JSON as 
an explicit schema or dynamically generates schemas of the existing Java objects. 
Since data is stored with its schema (self-describing), Avro is compatible with scripting 
languages. While not perfect (for example Avro currently does not have a way to 
represent a civil date-time) these exceptions can generally be worked around. We 
receive the Hospital data from a database snapshot. Apache Sqoop 
(​https://sqoop.apache.org/​) and Apache Nifi (​https://nifi.apache.org/​) are the most 
popular open-source software solutions for exporting databases to Avro format.  
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Figure S3: High level view of clinical database migration from Hospitals to STARR 
data lake.  
Once in Avro, the databases are then uploaded to cloud and imported in GCP BigQuery 
(BQ, ​https://cloud.google.com/bigquery/​) as a dataset for subsequent processing (see 
Figure S3). BQ is a highly performant analytical data warehousing technology that 
supports ANSI-compliant SQL and a powerful Application Programming Interface (API). 
It is not a transactional database like postgreSQL. While Stanford has exceptional 
on-premise computing resources, we believe that BQ provides a better overall query 
performance experience with significantly less IT overhead. It is not a low latency 
workflow, but the database scales exceptionally well for Big Data. BQ has proven to be 
highly performant for large scale GWAS [Pan2017].  
At Stanford, we benchmarked a set of five complex queries using our highly optimized 
Oracle database running on the state-of-the-art on-premise infrastructure, and the same 
data, as BigQuery dataset via Avro (Figure S3). These queries were submitted by the 
Honest Broker team as representative as typical queries requiring complex joins. The 
results of the benchmarking are presented in Table S3. We see that queries on 
BigQuery execute 10-100x faster than on Oracle. 
# Time on BigQuery  
(in sec) 
Time on Oracle  
(in sec) 
Processed data size  
(in GB) 
1  3.2 521  2.5 
2 6.3 704 19.8 
3 47 867 152.9 
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4 9.03 587 24.5 
5 102  1,200 33.3 
Table S3: Performance benchmarking of Oracle vs BigQuery, using a set of five 
complex queries.  
 
Section 4: Data processing 
In this section, we present our strategy for reproducible cloud agnostic petascale data 
processing using open standards.  
We leverage the significant investment in development and evaluation of workflow 
orchestration frameworks (aka workflow engines or pipeline frameworks) [Leipzig2017] 
in recent years. For our workflow framework (Figure S4), we adopt Common Workflow 
Language (CWL, ​https://www.commonwl.org/​) and Cromwell workflow execution engine 
(​https://github.com/broadinstitute/cromwell​). We evaluated a number of existing 
workflow orchestration frameworks by deploying and testing the software - Apache 
Airflow (​https://airflow.apache.org/​), Cromwell, Toil [Vivian2017], and Arvados 
(​https://arvados.org/​). Cromwell workflow executor engine was selected due to its broad 
range of platform support, its maturity on the GCP, and its ease of deployment. 
To support downstream reproducible science [Munafò2017], and data management 
efficiency, we consider the following requirements to be critical for our data processing: 
● Ability to track provenance of all outputs and every intermediate step - track 
every dependent source data and intermediate transformation so consumer of 
output has full visibility and understanding of where it came from. In our design, 
the source data is immutable (snapshots, not live databases or streams). 
● Ability to control reproducibility of all outputs including, a) ability to archive all 
versions of inputs including option to support purging to manage cost vs. 
reproducibility tradeoff, b) ability to transform in a deterministic fashion, c) ability 
to retain all software or logic used for transformation steps so we can run it in the 
future.  
● Ability to efficiently re-run transformations when new versions (snapshots) of the 
source data become available ​i.e.​, run transformations when things change, not 
on a schedule 
● Ability to add quality checks in each transformation step, so pipelines fail early 
rather than letting errors propagate 
 
Aside from selection of a workflow manager, these requirements also lead to design 
considerations. For example, is a monolithic step in the transformation pipeline better 
than loosely coupled steps? Loosely coupled steps are better for progress monitoring, 
workflow transparency, and enable intermediate stop and restart while tightly coupled 
steps offer better reproducibility and version compatibility. In another example, what 
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should constitute the archival “raw" data? While the original database (e.g., Oracle) 
dump can be stored as the raw, it is a proprietary and large file. Alternatively,  the highly 
compressed and standard avro can be the “raw” but is also less reliable due to potential 
bugs in Oracle technology stack or our data processing code used transformation steps. 
 
Figure S4: Workflow framework supports cloud services and user written tools. 
A STARR data pipeline corresponds to a top level CWL workflow. Configuration is the 
CWL definitions of workflows and their command line interfaces (Tools). Technology 
adapters are implemented through the use of containerization (Docker) to better support 
reproducibility and portability. These adapters are organized into two main categories:  
A. Tool adapters consisting of self contained containers that focus on a specific set 
of functionality, for example, text de-identification. Scaling of tools is explicitly 
managed by the workflow framework by instantiating multiple instances across a 
distributed computing resource along with managing the partitioning of work 
among instances.  
B. Service adapters to general purpose technologies that reside outside the 
containers in which the adapters live. Services are self scaling and not 
dependent on the workflow framework for scalability. For example, for BigQuery, 
our workflow framework provides a service adapter with similar capabilities to 
Google’s BigQuery command line tool 
(​https://cloud.google.com/bigquery/docs/reference/bq-cli-reference​). However, 
instead of simply wrapping this command line tool, its capabilities are mimicked 
where appropriate by leveraging BigQuery Java Client APIs 
(​https://googleapis.dev/java/google-cloud-clients/latest/index.html?com/google/cl
oud/bigquery/package-summary.html​) so that functionality can be more easily 
adapted and extended to work within the framework. Additions in functionality 
include, i) Data-quality-checks that enables the execution of a BigQuery 
measurement query and then the execution of a list of predefined rules to ensure 
the measurements obtained match a given set of criteria (for example no null 
values in a column), ii) View-dataset that enables the creation/update of a 
dataset that comprises of authorized views on another dataset (for example, 
maintain a statically named latest dataset of a series of snapshot datasets), and 
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iii) Metadata that adds support for querying the tables in a dataset and individual 
table schemas in a way that interoperates with CWL’s command line interface. 
Section 5: Data transformation from EHR to OMOP CDM 
In this section, we highlight the ETL (Extract, Transform, Load) processes that take us 
from Clarity data to OMOP data.  
RIT receives Epic Clarity Electronic Health Records (EHR) data from the two Stanford 
Hospitals: Adult Hospital (aka Stanford Health Care, ​https://stanfordhealthcare.org/​) and 
Children’s Hospital (aka Lucile Packard Children’s Hospital, 
https://www.stanfordchildrens.org/​). Epic Clarity contains data from the clinics that are 
part of the University Healthcare Alliance (​https://universityhealthcarealliance.org/​) and 
Lucile Packard Healthcare Alliance 
(​https://www.stanfordchildrens.org/en/about/our-network​). RIT also receives HL7 feeds 
from the two Hospitals such as Admit Discharge Transfer (ADT), and Billing Account 
Record (BAR) and the Social Security Administration Death Master File (DMF) provided 
to the National Technical Information Service [Levin2019].  
For our first launch of OMOP dataset, we limit the source data to Epic Clarity. The 
transformation process from Clarity to the OMOP-CDM can be summarized in five 
processes: ETL specifications, ETL code, mappings, data quality and data release. To 
design our ETL we current use OMOP-CDM v 5.3.1.The OHDSI consortium OMOP 
CDM github repository 
(​https://github.com/OHDSI/CommonDataModel/releases/tag/v5.3.1​) specifies a list of all 
the tables present in the 5.3.1 schema and the explanation for each one of the columns. 
The repository also contains a guide to populate each of the tables, THEMIS rules 
(​https://github.com/OHDSI/Themis​), which contain high level specifications for ETL. 
Those rules specify among other things a criteria for patient and clinical events inclusion 
and, what information is expected at each one of the fields. As OMOP is a 
patient-centric model, a patient is only brought in, iff, a patient has at least one qualified 
clinical event in Clarity. An event is considered a qualified event if it actually happened 
to the patient. A medication that was ordered but never administered to the patient will 
not be brought in into the CDM. There are also a large number of note records, ~51 
million, that do not contain any text and are suspected to be EHR artifacts such as failed 
attempts to create a clinical note that get registered in the Epic database. These are 
excluded from OMOP ETL.  
In Table S5.1, we present NCATS CTSA Common Metrics 
(​https://ncats.nih.gov/ctsa/projects/common-metrics​) from CTSA Program’s coordinating 
center, Center for Leading Innovation and Collaboration (CLIC). These metrics were 
established as a common framework across the consortium of 58 CTSA centers in 
order to maximize the consortium’s impact. Our OMOP database shows that over 60% 
of the patients have a diagnosis (ICD 9/10), over 40% have medication information 
(RxNorm), ~75% have lab information (LOINC), and over 90% of patients have clinical 
notes. 
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 Data Domain 
Count of 
patients (in 
millions) % of patients 
1 
Total patients in the database = Unique patients with at 
least one encounter and at least one event 2.7  
2 
Unique patients with at least one encounter and at least 
one event and administrative sex values 2.7 100% 
3 
Unique patients with at least one encounter and at least 
one event and age or DoB 2.7 100% 
4 At least one encounter 2.7 100% 
5 At least one diagnosis (​an ICD 9/10 or SNOMED value) 1.8 67% 
6 At least one procedure (an ICD 9/10 or CPT) 2.6 95% 
7 At least one medication (RxNorm) 1.3 46% 
8 At least one measurement / lab result (LOINC) 2.1 78% 
9 At least one device exposure 0.3 10% 
10 At least one observation 1.9 69% 
11 At least one notes / narratives 2.5 91% 
Table S5.1: NCATS CTSA Common Metrics output  
One of the main efforts to transform EHR data, Clarity, to the OMOP-CDM is the 
mapping of all the clinical information into standardized codes in the OHDSI OMOP 
vocabulary. The OHDSI OMOP vocabulary is a compendium of multiple terminologies 
and ontologies similar to the UMLS metathesaurus [UMLS2009]. The OMOP 5.3.1 
vocabulary is organized across 39 domains, 371 classes and 430 relationships 
containing more than 6 million codes from 91 -vocabularies. By working with 
standardized codes, the ambiguity around specific use of strings, values or codes is 
reduced. The mapping process implies the translation of raw information (e.g. a string 
such as “ml”) or codes in controlled terminologies or vocabularies (e.g. ICD10 R49.1) to 
standard codes in the OHDSI vocabulary. Figure S5.1 and table S5.2 show the 
improvement in standardized codes achieved over the raw Clarity data received from 
the Hospital. In some cases, Research IT had to develop a large number of custom 
codes (e.g. device exposure). 
 Unique Concept IDs 
cdm_table Standard 
(from 
Clarity) 
Standard (by 
RIT) 
Standard 
and Custom 
(by RIT) 
Device_exposure (SNOMED) 10 114 1,455 
Measurement (LOINC) 4,783 3,040 3,040 
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Condition_occurrence (an ICD 9/10 or 
SNOMED) 
14,814 3,359 3,359 
Procedure_occurrence (ICD 9/10 or CPT) 28,204 2,382 2,382 
Drug_exposure (RxNorm) 9,444 2,567 3,205 
Table S5.2: Unique standardized codes delivered by Hospital Clarity and augmented by 
Research IT’s ETL pipelines.  
 
 
Figure S5.1: Shows the improvement to standardized OMOP CDM vocabularies in 
Clarity data (blue) vs the additional augmentation (orange) achieved in the OMOP 
dataset.  
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We use the OHDSI Achilles Heel tool for data quality analysis. This tool precomputes 
~170 data characterizations that are iteratively used to improve the CDM. The 
improvements trigger three different actions: record removal, bug fixing and mapping 
changes.  In an example of record removal, we have cases where some clinical events 
occurring prior to birth date. This is essentially a data entry error where proper 
adjudication is not feasible, and as a consequence the only option is to remove the 
record from the CDM. Mapping changes occur in two scenarios. The first is when the 
source data does not contain the mappings and it is necessary to do custom mapping 
given the raw data (e.g. a string). The second is when a different table in the source 
Clarity data is needed - the two Hospitals have different workflows resulting in different 
tables being populated in Clarity. This data quality process integrates with all the 
transformation by possibly modifying the specs and the subsequent code. It is 
essentially an iterative process of continuous improvement.  
Figure S5.2 shows the distribution of words in notes. There are `~100M notes 
containing 33 billion words. Median number of words in a note is ~100, and ~9% notes 
have >1000 words, and 0.04% of the notes have >5,000 words. We investigated the 
notes that contained >5,000  words and found a few different reasons for their 
uncommon length. In some cases,  the long notes include information of laboratory 
tests, radiology reports, medications and checklists beyond the regular use of those 
elements in a note. Discharge summaries sometimes contain information that is already 
present in progress notes as a way to document the progression of the patient during 
the stay. In some imaging reports, we found detailed information about the anatomy 
observed, specifically for cases where multiple systems or organs are being evaluated. 
Lastly, one of the EHR migrations resulted in merging of notes for a subset of our 
patients.  
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Figure S5.2: Distribution of words in ~100 million clinical reports (notes). There are 
approximately 33 billion words in 100 million notes. 
Section 6: De-identification methods 
In this section, we present anonymization techniques used to produce the 
STARR-OMOP-deid dataset. The anonymized clinical text is stored in NOTE table of 
the OMOP CDM. 
Research IT achieves de-identification of STARR-OMOP data in accordance with NIST 
guidelines [NISTIR 8053] to meet the HIPAA Privacy Rule [HHS2002]. In particular, we 
use the Safe Harbor approach. Our approach to de-identification is similar to those 
presented by Ferrández ​et al​ [Ferrández2013] in that, we a) maximize patient 
confidentiality by redacting as much PHI as possible and may accidentally redact 
non-PHI; and b) leave de-identified data in a usable state preserving as much clinical 
information as possible. 
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Prior assessments [Fernandez2013] of clinical text de-identification techniques show 
that it is difficult to find a single approach that performs well in all cases. Clinical 
narratives can be fragmented and lack formatting, making the use of pre-trained 
traditional newswire Name Entity Recognition (NER) approaches limiting. Rule based 
techniques (e.g. pattern matching) are not scalable approaches. Research IT has 
developed a de-identification approach, TiDE (Text DEidentification), that combines a 
mix of pattern matching techniques, machine learning-based NER and Hiding in Plain 
Sight [Carrell2013]. While each of the techniques is only effective part of the time, 
together they are highly effective most of the time. We focus TiDE pipeline (Figure S6.1) 
on preserving patient privacy i.e., sensitivity of finding PHI is more important than 
specificity.  In the first step, we find the locations of HIPAA identifiers.   
TiDE has three separate sub-modules that find the HIPAA identifiers, a) the NLP name 
entity recognition module uses CoreNLP [Manning2014]] and can find random 
combinations of street name, city name, state name and zip code, b) the regular 
expression (regex) pattern matching to known patient PHI and, c) for entities like MRNs, 
SSN (e.g. 123-45-6789), email (e.g. john@example.org), IP, URL, we use an 
enumerated pattern matching.  
 
Figure S6.1: Shows the TiDE text de-identification workflow  
We selected CoreNLP [Manning2014], an open source software developed at Stanford 
for identifying names and addresses in the text. At the heart of CoreNLP is the Stanford 
Named Entity Recognizer (Stanford NER) also known as CRFClassifier. The software 
provides a general implementation of linear chain Conditional Random Field (CRF) 
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sequence models. CRFs have been known to perform well for clinical text 
de-identification [Deleger2013]. 
All HIPAA findings are stored in BigQuery. We then use BigQuery User-Defined 
Function (UDF, 
https://cloud.google.com/bigquery/docs/reference/standard-sql/user-defined-functions​) 
to select and merge all findings across the different methods to generate final list of 
candidate PHI that are then de-identified.  
 
Original  
PHI​ ​&​ PII  
Safe Harbor  
Lookup, ​NLP​, ​Reg-Ex​, 
Leaked PHI 
TiDE 
Safe harbor,​ Surrogate 
PHI / PII, ​hiding PHI 
Jonathan Smith​, 41 years 
… 
children, ​Lynn​ and ​David 
and  ​Madison​ … 
oncologist, ​Dr. White​ on 
5/13/10​ to schedule MRI 
… 
DRE from ​5/7​ was ...  
to call ​Mr. Smith​ on ... 
 
[**PAT-FN]​ ​[**PAT-LN]​, 41 
years … 
children, ​[**NAME]​ and 
[**NAME]​ and ​Madison​ … 
oncologist, ​Dr. ​[**DR-LN] 
on 
[**5/31/10]​ to schedule 
MRI  … 
DRE from ​5/7​ was ... 
to call Mr. ​[**PAT-LN]​ ​on 
… 
Tom Jones​, 41 years … 
children, ​Mary​ and ​Joe 
and ​Madison​ … 
oncologist, ​Dr. Howe​ on 
5/31/10​ to schedule MRI 
… 
DRE from ​5/7​ was ... 
to call ​Mr. Jones​ ​on … 
Table S6: Illustration of our TiDE output.  
For names and places, which are two of the three most frequent PHI in clinical text data, 
we use a surrogate approach [Carrell2013] aka Hiding in Plain Sight (HIPS) illustrated in 
Table S6. In column 1, we show original PHI (patient and children names, date of visits) 
and PII (doctor’s name). In column 2, we show a typical Safe Harbor implementation, a) 
patient and doctor names are identified and redacted using pre-existing information in 
Clarity database, b) one of the dates is identified using RegEx and jittered, and b) two of 
the children names are identified using NLP approaches and redacted. In column 3, we 
show the impact of surrogate approach to names. Here, one of the names (Madison) 
and a procedure date (5/7), previously undetected, are hidden with the HIPS approach. 
At the time of writing, the name replacement is gender aware but not ethnicity aware. 
Addresses are replaced randomly.  
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Figure S6.2: Hiding in Plain Sight Surrogate Database.  
 
The development of surrogate database is illustrated in Figure S6.2. We collate the 
following sources, a) Bay Area census with addresses (bayareacensus.ca.gov), b) 
Health resources and services administration database with US addresses 
(data.hrsa.gov), c) FDA website with addresses (data.gov), d) Social security database 
with baby names (ssa.gov), and e) Medicare services database with physician names 
(data.cms.gov). 
Recently, the HIPS team presented the parrot attack [Carrell2019] and for this attack to 
succeed, we will need to assume an attack scenario where a) the attacker will 
maliciously hack in our secure data center and download de-identified data, b) the 
attacker will attempt to tag all real and surrogate PHI in the data, c) attacker will have 
access to data used to train our models, and d) attacker will be able to train a model to 
match ours. We believe that our system does not support this attack scenario. Firstly, 
Research IT does not provide any training data and secondly, our pipeline uses a 
collection of different machine learning algorithms and Safe Harbor method ​i.e.​, it is not 
a single model that can be reverse engineered. 
We use a manual QC process illustrated in Supplementary Figure S6.3. In the case of 
clinical notes, we start with top 200 different note types that occur most frequently, pick 
1000 random notes from these and of these, we pick a 100 that have a high amount of 
PHI found or high number of words found. These hundred go through a manual review 
for false negatives ​i.e.​, we look for PHI left behind. For flowsheet (observational 
measurements) data, we take 80,000 rows and take them through a word frequency 
count. We then manually review the lowest frequency 10,000 words for potential PHI.  
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Figure S6.3: A stratified random sampling method for manual QC.  
We considered using the i2b2 2014 ​Deidentification & Heart Disease​ dataset 
[Stubbs2014] to evaluate the performance of our de-identification pipeline but we could 
not find a meaningful set of comparison metrics due to procedural differences between 
the two. Firstly, we heavily use ​a priori​ information for a given patient. This information 
is not available for the i2b2 dataset. Secondly, our interpretation of the HIPAA Safe 
Harbor method is similar to the one used in MIMIC III [Johnson2016] and is different 
from the i2b2 dataset. For example, in the i2b2 dataset, ​age​ is considered PHI. 
However, in our case and in MIMIC III, only ages >89 are considered PHI. Other 
categories with difference from i2b2 approach include ​profession​ and ​location​. 
Profession only becomes an identifier when it is very unique (e.g. Apple CEO). Location 
for i2b2 dataset includes organization as PHI and not just addresses. As with profession 
an organization becomes an identifier only if it is very unique and can be easily linked 
with the patient. In our strategy we used CoreNLP to recognize generic locations and 
organizations, however, by no means is CoreNLP capable of removing mentions of 
obscure company names.  
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Figure S6.4: Shows distribution of PHI count in ~100 million notes.  
Figure S6.4 shows the distribution of PHI count found in notes. There are ~22 million 
notes with no PHI findings, and ~1.3M notes with more than 100 PHI findings. There are 
~33 billion words, of which 1.4 billion are determined as PHI findings ​i.e.​, approximately 
4% of the words are found to be PHI. Some of the notes with high volumes of PHI are 
due to the presence of repeated elements inside checklists produced by dropdown 
menus, laboratory results and vital signs. The most common repeated elements are 
dates and clinician’s names.  
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Figure S6.5: Distribution of different PHI types found in ~100 million notes. In the 
bottom graph, we present the occurrence of PHI by type. In the top graph, we present 
the methods used in finding a specific type of PHI. 
Figure S6.5 presents findings from our text anonymization pipeline. We observe that 
names, dates, and location are the most common PHI types. We also find that the 
“mixed bag” approach of finding PHI is useful. For example, for patient and physician 
names, ~60% are found using patient information lookup and an additional 40% are 
found using NLP. Dates, MRNs and phone numbers benefit from regex search. 
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Section 7: Processing clinical text to identify known medical 
concepts 
In this section, we present our method used to process clinical text to identify known 
medical concepts and store these concepts in the NOTE_NLP table in the OMOP CDM. 
Text processing tools transform the unstructured information inside the notes into 
structure information that can be queried and stored in structured tables. The amount 
and type of information extracted from clinical notes vary from tool to tool. Most of the 
tools focus their efforts in mapping mentions of diseases, signs, and symptoms into a 
controlled terminology such as ICD or SNOMED  (Figure S7.1). Through this mapping 
two different mentions such as “fever” and “temp > 37.5C” are mapped to the same 
concept inside a terminology. In this case the ICD-10 code R50.9.  
For populating concepts in the NOTE_NLP table, we use a pipeline developed by 
LePendu ​et al​ [LePendu2013], that has incorporated both negation detection and 
history detection. These contextual cues are based on NegEx [Chapman2001] and 
ConText [Chapman2007] and enable us to discern whether a term should ​not​ be 
attributed the current patient (e.g., ​lack of​ valvular dysfunction, or ​sister has​ muscular 
dystrophy).  The pipeline extracts term mentions ​i.e.​, string unique identifiers (SUI) 
within the UMLS [RRF2009] vocabulary. The terms are disambiguated (Figure S7.2) 
and then mapped to concepts in the OHDSI vocabulary (Figure S7.3) using an ETL 
similar to the OHDSI tool Ananke (​https://github.com/jmbanda/Ananke​) which maps 
from CUI to concepts. There are two ways to disambiguate via pre-processing, a) Word 
sense disambiguation algorithms that attempt to select the most likely sense of a string 
given the context, and b) the dictionaries used in the mapping are pruned and filtered 
using rules that attempt to increase precision.  STARR uses the latter approach, we 
exclude terms with less than four characters and those present in the list of ambiguous 
terms provided by UMLS  in AMBIGSUI.RRF.  
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Figure S7.1: An example of the mapping of term mentions of diseases and             
procedures from clinical notes into a controlled terminology such as SNOMED. 
 
Figure S7.2: An example of one ambiguous term (SUI) with two possible CUI’s.  
 
Figure S7.3: An example of the mapping of one term to the preferred concept_id in               
the OHDSI vocabulary.  
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In the pipeline developed by LePendu ​et al​ [LePendu2013], each concept can contain 
modifiers that affect their interpretation and use in research. A mention of “high blood 
pressure” does not ascertain that the patient is experiencing the symptom. Context is 
necessary for an adequate interpretation [Harkema2009]. If the sentence, “​family history 
of high blood pressure”, human intelligence can safely interpret that the patient is not 
the one that suffers from high blood pressure. To translate this into structured 
information we need to introduce concept modifiers. These modifiers allow us to 
enhance the interpretation of the mapped concepts. 
We populate the term_modifiers field in the NOTE_NLP table​ ​using the following 
strings: 
1. experiencer_other: The absence of this modifier implies that the clinical event 
associated with the concept is being experienced by the patient. In the two 
examples, a) “The ​patient​ has coronary artery disease” and, b) “Coronary artery 
disease in ​father​”, the modifier is present only in example b.  
2. history_of_past: If this modifier is present, the clinical event associated with the 
concept likely occurred in the past. In the three examples, a) “she ​has​ chest 
pain”, b) “She ​had​ hyperlipidemia” and, c) “​Will​ schedule screening mammogram 
at ​next visit​”; the modifier is present only in example a. 
3. polarity_negated: The absence of this modifier implies the concept is present for 
the patient. If this modifier is present, the concept is negated. In the two 
examples, a) “the patient ​does not​ have any neurologic deficits” and, b) “​she is 
being​ dialyzed”, the modifier is present only in example a. 
Table S7 shows the distribution of concepts from different vocabularies and domain 
found in clinical notes respectively. Column 2 shows total counts of the concepts found 
(sum = 1.9 billion) and column 3 shows the percentage of occurance. Column 4 shows 
total unique counts (sum = 122K) and column four shows the percentage of unique 
count occurance.  
 Vocabulary 
Total count 
(in millions) 
% of Total 
count 
Total unique 
concept 
count 
% of total 
unique 
concept 
count 
1 SNOMED 1,179 60.99 68,932 56.55 
2 RxNorm 47 2.46 12,755 10.47 
3 LOINC 407 21.03 8,008 6.57 
4 ICD10CM 9.6 0.50 7,113 5.84 
5 MeSH 116 5.79 6,745 5.53 
6 NDFRT 87 4.50 4,796 3.94 
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7 ICD9CM 8 0.41 3,688 3.03 
8 CPT4 9.5 0.49 3,302 2.71 
9 Multum 34 1.77 2,971 2.44 
10 SNOMED Veterinary 13 0.68 1,309 1.07 
11 HCPCS 1.7 0.09 878 0.72 
12 ICD10 0.9 0.05 690 0.57 
13 ATC 24 1.22 523 0.43 
14 ICD10PCS 0.1 0.01 125 0.10 
Table S7: Frequency of occurrence of top 14 vocabulary terms found as a result of text 
mapping.  
In the case of vocabularies, preference to SNOMED in OMOP is reflected in the data. 
The prevalence of vital signs and laboratory results in clinical notes, is reflected in 
LOINC being the second most common vocabulary. MeSH vocabulary includes the 
subject descriptors appearing in MEDLINE/PubMed, the NLM catalog database, and 
other NLM databases. The vocabularies NDFRT, RxNorm, Multum and ATC cover the 
mentions of drugs and chemicals within the clinical notes.  Two other vocabularies, CVX 
and NUCC, are found to have insignificant counts.  
Section 8: Nero, a secure data science platform 
In this section, we present our secure data science platform from where 
STARR-OMOP-deid can be accessed and analyzed. 
The approach of co-locating data with computing resources and analysis tools is 
popularized in platforms such as NCI Genomics Data Commons [Wilson2017] and Sage 
Synapse Platform [Ellrott2019]. Academic centers have also taken the initiative of 
developing Big Data science platforms [McPadden2019]. There are multiple secure and 
compliant workspaces offered by commercial entities (e.g. DNAnexus, 
https://www.dnanexus.com/​) and Supercomputing facilities (e.g. San Diego 
Supercomputer Center Sherlock Cloud, ​https://sherlock.sdsc.edu/​), but use of these 
facilities for High Risk or PHI data requires lengthy contractual processes. We believe 
that a secure internal infrastructure, that is integrated with institutional compliance 
processes, leads to reduced friction for researchers.  
To support the High Risk nature of the underlying data, Stanford has built a PHI secure 
data science platform, Nero (​http://med.stanford.edu/nero​), named after the fictional 
armchair detective Nero Wolfe (​https://en.wikipedia.org/wiki/Nero_Wolfe​). The access to 
STARR-OMOP-deid dataset is made available in Nero. The platform is a collaboration 
between Research IT at Stanford Medicine and Stanford Research Computing Center 
(SRCC) at University IT. The SRCC team has in-depth expertise across the spectrum of 
This document is supplemental to the main manuscript, “A new paradigm for accelerating clinical data science at Stanford Medicine” 
23 of 26 
HPC and data management services. The SRCC team develops, and manages the 
Nero platform and provides secure workspaces and research computing support to the 
users.  Nero has a private cloud infrastructure based on open source components 
hosted at Stanford Research Computing Facility (SRCF) with direct connectivity to a 
100 gigabit network connection to available Research and Education Networks via 
CENIC’s California Research and Education Network (​https://cenic.org/​). Nero is also 
integrated with Stanford secured public clouds. The platform allows researchers to 
access Stanford data resources like STARR and also allows researchers to bring their 
own data to the platform.  
The on-premise Nero environment, at the time of writing, is comprised of 6 Dell C4140 
and 18 Lenovo SD530 servers. Servers have either dual Intel Xeon Silver or dual Intel 
Xeon Gold processors, providing 24 cores with 384 GB of RAM per server.  These 
compute nodes use Ubuntu running Docker containers, with relevant software. 
Workloads are scheduled using Slurm Workload Manager 
(​https://slurm.schedmd.com/documentation.html​) , and configurations are managed by 
Metal as a Service (MAAS, ​https://maas.io/​), Juju as a Service (JaaS, ​https://jaas.ai/​), 
and Kubernetes container orchestration service (​https://kubernetes.io/​).  Nero also has 
24 NVidia V100 Tensor Core (​https://www.nvidia.com/en-us/data-center/v100/​) and 4 
NVidia Tesla P100 (​https://www.nvidia.com/en-us/data-center/tesla-p100/​) GPUs 
totaling 28 GPU cores available to researchers.  For storage, Nero has 630 TB of Ceph 
(​https://docs.ceph.com/docs/master/​) general-purpose storage on Lenovo storage 
arrays, plus 30 TB of high-IOPS storage.  Storage is encrypted via Linux Unified Key 
Setup-on-disk-format (or LUKS) Advanced Encryption Standard (AES) 265-bit 
encryption. 
Finally, Nero makes commonly used research tools available using two approaches, a) 
for publicly available tools, the Nero team containerize the application stack and take it 
through a rigorous process of vulnerability scanning (e.g. OHDSI analytical tools), and 
b) for software-as-a-service (SaaS), the team partners with the provider to integrate the 
service with the Nero platform (e.g. ​https://stanford.md.ai/​) in compliance with Stanford 
ISO requirements. The system administration of Nero platform includes a fully managed 
security service and research computing support. 
Section 9: Data and tool access  
In this section, we present how researchers access data and data science tools in the 
secure Nero environment. 
A researcher can request access to Nero as long as they are affiliated with a Stanford 
Principal Investigator (PI) and have a Stanford identity. Once the researcher becomes 
an authorized user, they get access to Nero via Stanford Virtual Private Network (VPN) 
and Stanford two factor authentication. Researcher needs to access Nero using a 
secure Stanford endpoint (​i.e.​, laptop) that meets minimum security requirements for 
High Risk and PHI data. Stanford researchers are also required to take HIPAA training 
(​https://privacy.stanford.edu/training/hipaa​). To access STARR-OMOP-deid data, 
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Stanford researcher then completes the requisite Data Use Agreement, also referred to 
as Data Privacy Attestation, attesting to the fact that they are requesting access to a 
High Risk non-human subject exploratory dataset. The attestation goes through the 
researcher's responsibilities for the data handling. Once a researcher is on Nero, and 
DUA is completed, they get access to the STARR-OMOP-deid BigQuery dataset and 
are added to a user support slack channel. 
Once on Nero, they can use an interactive terminal or use Jupyter Hub to launch a 
preferred kernel (e.g. R or Python) or use batch mode via SLURM job scheduler. They 
can access their workspaces on-premise or Cloud and their preferred applications, bring 
their own data to their workspace, run batch mode or real time analysis, request new 
applications or troubleshooting help from the system administration team, and share 
code with collaborators using Stanford gitlab. 
In Table S9.1​, we present performance results from common queries as a result of 
using Google BigQuery to store the OMOP data (Supplementary material, Section 3). 
OHDSI development community has made an explicit effort to support a number of 
databases including traditional relational data warehousing technologies such as 
PostgreSQL, Oracle, Microsoft SQL, as well as Big Data warehousing technologies 
such as Azure Synapse, IBM Netezza, and Amazon RedShift, Cloudera Impala and 
Google BigQuery. The OHDSI SqlRender package 
(​https://github.com/OHDSI/SqlRender​) and JDBC drivers require performance tuning to 
support a new database type. RIT worked closely with Odysseus Data Services Inc, 
OHDSI consortium’s ATLAS development team, to optimize performance of Google Big 
Query for OHDSI ATLAS tool (Supplementary Section 3). These queries are from the 
OHDSI Achilles tool (​https://github.com/OHDSI/Achilles/tree/master/inst/sql/sql_server​) 
and are used to characterize the data quality. Out of 725 total queries available in 
Achilles, 660 queries took less than 17 seconds, and median execution time was 3 sec. 
The longest query took 1207 seconds (20 min) and processed 13GB of data.  
 
Number of Queries 1.0 
Mean Execution Time (s) 9.4 
Median Execution Time (s) 2.8 
Min Execution Time (s) 0.4 
Max Execution Time (s) 1,207.4 
Total Execution Time (hr) 1.9 
Volume of data traversed by the queries (GB) 726.3 
Source of Queries Achilles Analyses Queries 
Table S9.1: We run OHDSI Achilles QA SQL queries (725) and report the statistical 
query times. 
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Researchers also get access to OHDSI ATLAS Cohort tool 
(​https://ohdsi-atlas.stanford.edu/​).  OHDSI support for BigQuery platform is relatively 
new. Research IT has worked closely with Odysseus Data Services Inc, developers of 
OHDSI ATLAS cohort analysis tool, to optimize ATLAS performance for BigQuery. We 
present the results of performance benchmarking using postgreSQL and BigQuery for 
the commonly available ​Medicare Claims Synthetic Public Use datafiles (DE-SynPUF, 
https://www.cms.gov/Research-Statistics-Data-and-Systems/Downloadable-Public-Use-
Files/SynPUFs/DE_Syn_PUF​)​.  In order to benchmark postgreSQL vs BigQuery, 
ATLAS was installed on Google Compute Engine instance with parameters presented in 
Table S9.2. We used OHDSI CDM DDL scripts to build the two data structures - 
PostgreSQL (​https://github.com/OHDSI/CommonDataModel/tree/v5.3.1/PostgreSQL​) 
and BigQuery (​https://github.com/OHDSI/CommonDataModel/tree/v5.3.1/BigQuery​). In 
case of PostgreSQL indexes and constraints were applied. For BigQuery, no additional 
configuration was applied. Standard suite of tests used for ATLAS benchmarking 
(​https://github.com/odysseusinc/TestScripts/tree/master/scripts​), were run.  Each test 
was executed separately per database to avoid caching and resource contention. 
Results of the various tests are presented in Table S9.3. 
 
ATLAS compute instance 
configuration 
Deployed ATLAS 2.7.4 with 2 vCPUs, 15 GB memory, 
50Gb storage, and CentOS 7 
DE-SynPUF dataset OMOP CDM ver 5.3.1​, was used with 2M patients for 
measurement with vocabularies from ATHENA October 
2019 
PostgreSQL VM instance Deployed PostgreSQL v11, latest available in GCP with 
4 vCPUs, 15 GB memory, 903 GB SSD storage 
PostgreSQL configuration temp_file_limit: 2,147,483,647, max_connections: 40, 
maintenance_work_mem: 960,000, 
checkpoint_completion_target: 0.7, 
default_statistics_target: 100, random_page_cost: 1.1, 
work_mem: 48,000, max_wal_size: 2,100,000,000.  
Table S9.2: ATLAS benchmarking setup on GCP. 
 
# Action 
PostgreSQL  
(SynPUF 2m) 
BigQuery  
(SynPUF 2m) 
1 Vocabulary search (aspirin) 00:00:17 00:00:17 
2 Profile search (2320055) 0:00:03 00:00:25 
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3 Cohort generation (counts): Celecoxib new 
users (Target Cohort) 
00:08:08 00:02:21 
4 Characterization generation: Aspirin users 
vs Сlopidogrel users characterization 
00:10:20 00:07:38 
5 IR generation: Incidence rate valsartan 
tutorial 
00:16:39 00:04:35 
6 PLE: Celecoxib vs Diclofenac in major GI 
bleeding 
12+ hours 222m 43s 
7 PLP: Clopidogrel leading to pneumonia 12+ hours 87m 09s 
8 Cohort Pathway: PNAS Characterizing 
treatment pathways replication 
00:38:35 00:10:14 
Table S9.3: ATLAS benchmarking results using a synthetic dataset, SynPUF. 
Section 10: User training  
In this section, we present the training material available to our community. 
As part of data access, researchers also get access to technical specification 
documents, training datasets - a one percent STARR-OMOP-deid dataset (for testing 
SQL queries ) and a synthetic dataset Data Entrepreneurs’ Synthetic Public Use File 
(DE-SynPUF, 
https://www.cms.gov/Research-Statistics-Data-and-Systems/Downloadable-Public-Use-
Files/SynPUFs/DE_Syn_PUF.html​) in OMOP 5.3.1 format, and access to Stanford 
gitlab with Jupyter notebooks compatible code. The specifics of ETL code used to 
transform data from Clarity to OMOP is made available upon request. 
Research IT offers hands-on training sessions that help researchers with understanding 
and use of OMOP CDM, STARR-OMOP-deid dataset, and the Nero research 
computing environment. 
This document is supplemental to the main manuscript, “A new paradigm for accelerating clinical data science at Stanford Medicine” 
